PMID- 34439070
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20210830
IS  - 2079-6382 (Print)
IS  - 2079-6382 (Electronic)
IS  - 2079-6382 (Linking)
VI  - 10
IP  - 8
DP  - 2021 Aug 22
TI  - Anti-MRSA Cephalosporin versus Vancomycin-Based Treatment for Acute Bacterial 
      Skin and Skin Structure Infection: A Systematic Review and Meta-Analysis of 
      Randomized Controlled Trials.
LID - 10.3390/antibiotics10081020 [doi]
LID - 1020
AB  - This systematic review and meta-analysis of randomized controlled trials (RCTs) 
      compared the clinical efficacy and safety of anti-MRSA cephalosporin and 
      vancomycin-based treatment in treating acute bacterial skin and skin structure 
      infections (ABSSSIs). PubMed, Embase, Cochrane Central Register of Controlled 
      Trials, Turning Research into Practice, and ClinicalTrials.gov databases were 
      searched for relevant articles from inception to 15 June 2020. RCTs comparing the 
      clinical efficacy and safety of anti-MRSA cephalosporin with those of 
      vancomycin-based regimens in treating adult patients with ABSSSIs were included. 
      The primary and secondary outcomes were clinical response at the test-of-cure 
      assessments and risk of adverse events (AEs), respectively. Eight RCTs were 
      enrolled. The clinical response rate was not significantly different between 
      anti-MRSA cephalosporin and vancomycin-based treatments (odds ratio [OR], 1.05; 
      95% CI, 0.90-1.23; I(2) = 0%). Except for major cutaneous abscesses in which 
      anti-MRSA cephalosporin-based treatment was associated with a lower clinical 
      response rate than vancomycin-based treatment (OR, 0.62; 95% CI, 0.40-0.97; I(2) 
      = 0%), other subgroup analyses according to the type of cephalosporin 
      (ceftaroline or ceftobiprole), type of infection, and different pathogens did not 
      show significant differences in clinical response. Anti-MRSA cephalosporin-based 
      treatment was only associated with a higher risk of nausea than vancomycin-based 
      treatment (OR, 1.41; 95% CI, 1.07-1.85; I(2) = 0%). In treating ABSSSIs, the 
      clinical efficacy of anti-MRSA cephalosporin is comparable to that of 
      vancomycin-based treatment, except in major cutaneous abscesses. In addition to 
      nausea, anti-MRSA cephalosporin was as tolerable as vancomycin-based treatment.
FAU - Chen, Ching-Yi
AU  - Chen CY
AD  - Division of Chest Medicine, Department of Internal Medicine, E-Da Hospital, 
      I-Shou University, Kaohsiung 82445, Taiwan.
FAU - Chen, Wang-Chun
AU  - Chen WC
AD  - Institute of Biotechnology and Chemical Engineering, I-Shou University, Kaohsiung 
      82445, Taiwan.
AD  - Department of Pharmacy, E-Da Hospital, Kaohsiung 82445, Taiwan.
FAU - Lai, Chih-Cheng
AU  - Lai CC
AD  - Department of Internal Medicine, Kaohsiung Veterans General Hospital, Tainan 
      Branch, Tainan 71051, Taiwan.
FAU - Shih, Tzu-Ping
AU  - Shih TP
AD  - Department of Family Medicine, Kaohsiung Veterans General Hospital, Tainan 
      Branch, Tainan 71051, Taiwan.
FAU - Tang, Hung-Jen
AU  - Tang HJ
AD  - Department of Medicine, Chi Mei Medical Center, Tainan 71004, Taiwan.
LA  - eng
PT  - Journal Article
DEP - 20210822
PL  - Switzerland
TA  - Antibiotics (Basel)
JT  - Antibiotics (Basel, Switzerland)
JID - 101637404
PMC - PMC8388936
OTO - NOTNLM
OT  - acute bacterial skin and skin structure infection
OT  - ceftaroline
OT  - ceftobiprole
OT  - methicillin-resistant Staphylococcus aureus
OT  - vancomycin
COIS- The authors declare no conflict of interest.
EDAT- 2021/08/28 06:00
MHDA- 2021/08/28 06:01
PMCR- 2021/08/22
CRDT- 2021/08/27 01:02
PHST- 2021/07/03 00:00 [received]
PHST- 2021/08/18 00:00 [revised]
PHST- 2021/08/21 00:00 [accepted]
PHST- 2021/08/27 01:02 [entrez]
PHST- 2021/08/28 06:00 [pubmed]
PHST- 2021/08/28 06:01 [medline]
PHST- 2021/08/22 00:00 [pmc-release]
AID - antibiotics10081020 [pii]
AID - antibiotics-10-01020 [pii]
AID - 10.3390/antibiotics10081020 [doi]
PST - epublish
SO  - Antibiotics (Basel). 2021 Aug 22;10(8):1020. doi: 10.3390/antibiotics10081020.